Phase II Exploratory Trial to Evaluate the Efficacy and Safety of NOV120101 (Poziotinib) in Lung Adenocarcinoma Patients With Acquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors
Phase of Trial: Phase II
Latest Information Update: 18 Aug 2015
At a glance
- Drugs Poziotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Hanmi Pharmaceutical
- 13 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 03 Jul 2014 Planned End Date changed from 1 Dec 2015 to 1 Sep 2014 as reported by ClinicalTrials.gov record.